A bio-predictive release assay for liposomal prednisolone phosphate.

Area of Science:

• Nanomedicine
• Pharmaceutical Sciences
• Drug Delivery

Background:

• Predictive performance assays are vital for nanomedicine development and approval.
• Current methods lack compendial standards for comparing nanomedicine formulations.
• Incomplete understanding of in vivo release necessitates extensive, costly animal studies for bioequivalence.

Purpose of the Study:

• To develop a discriminatory and biopredictive in vitro release test method for liposomal prednisolone phosphate.
• To establish a reliable standard for comparing nanomedicine formulation prototypes.
• To reduce the cost and duration of nanomedicine development by minimizing animal studies.

Main Methods:

• Model-informed deconvolution to identify in vivo target release.
• Discrete L-optimal experimental design for method refinement.
• Three-point specification evaluating early, intermediate, and late release phases.
• Assessment of shear responses and influence of protein composition in release media.

Main Results:

• A discriminatory and biopredictive in vitro release method was developed for liposomal prednisolone phosphate.
• The method identified key in vivo release phases (T-5%, T-20%, T-40%) for comparison with reference products.
• Protein concentration, particularly fetal bovine serum, significantly influenced liposome release and method discriminatory performance under shear stress.

Conclusions:

• The developed in vitro method offers deep insights into liposome release dynamics.
• This workflow facilitates in vitro bioequivalence evaluation for nanomedicines.
• The method provides a potential alternative to extensive animal testing for nanomedicine development.